BVS

Bioventus Inc. NASDAQ

Healthcare ·Medical - Devices ·US · bioventus.com

$10.68

Mkt Cap $722.4M

52w Low $5.81 98.4% of range 52w High $10.76

50d MA $9.24 200d MA $7.78

P/E (TTM) 29.7x

EV/EBITDA 7.2x

P/B 3.0x

Debt/Equity 1.7x

ROE 14.8%

P/FCF 6.9x

RSI (14) —

ATR (14) —

Beta 0.69

50d MA $9.24

200d MA $7.78

Avg Volume 403.7K

About

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions compr…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	BMO	0.22	0.24	+9.1%	9.10	-1.5%	-7.6%	-5.4%	-2.6%	-2.2%	-5.5%	—
Nov 4, 2025	BMO	0.21	0.15	-30.2%	7.55	-0.7%	-2.3%	-0.9%	-1.3%	-0.8%	+2.0%	—
Aug 6, 2025	BMO	0.22	0.21	-4.5%	7.29	-0.3%	-4.9%	-5.1%	-4.9%	+0.3%	+3.3%	—
May 6, 2025	BMO	0.06	0.08	+33.3%	6.20	+0.5%	+6.3%	+9.7%	+7.7%	+8.7%	+5.5%	—
Mar 11, 2025	BMO	0.08	0.15	+87.5%	10.80	+0.1%	-6.8%	-11.0%	-11.0%	-9.3%	-11.5%	—
Nov 5, 2024	BMO	0.06	0.06	+0.0%	11.48	+4.5%	-1.7%	-2.1%	+3.0%	+8.4%	+3.1%	—
Aug 6, 2024	BMO	0.07	0.19	+171.4%	8.09	+3.3%	-7.8%	-6.1%	-6.2%	-6.6%	-2.3%	—
May 7, 2024	BMO	-0.05	0.07	+240.0%	5.12	+5.5%	-1.6%	+6.6%	+5.5%	+11.7%	+17.0%	—
Mar 12, 2024	BMO	0.06	0.07	+16.7%	5.60	+1.8%	-5.5%	-7.3%	-2.7%	-2.0%	-3.6%	—
Nov 7, 2023	BMO	0.06	0.05	-16.7%	3.61	-0.6%	+5.5%	-2.5%	-2.5%	+2.5%	+4.2%	—
Aug 8, 2023	BMO	0.03	0.14	+366.7%	3.88	+6.7%	+5.4%	+17.8%	+16.5%	+22.2%	+27.3%	—
May 16, 2023	BMO	-0.11	-0.26	-136.4%	1.20	+0.0%	+9.2%	+21.7%	+62.5%	+74.2%	+102.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 6	Barrington Research	Maintains	Outperform → Outperform	—	$9.10	$8.96	-1.5%	-7.6%	-5.4%	-2.6%	-2.2%	-5.5%
Mar 6	Craig-Hallum	Maintains	Buy → Buy	—	$9.10	$8.96	-1.5%	-7.6%	-5.4%	-2.6%	-2.2%	-5.5%
Mar 17	Canaccord Genuity	Maintains	Buy → Buy	—	$9.61	$9.54	-0.7%	+2.0%	-0.5%	+3.3%	+1.4%	+0.4%
Dec 17	JP Morgan	Upgrade	Underweight → Neutral	—	$11.15	$11.40	+2.2%	+0.0%	-4.8%	-5.7%	-4.3%	-4.5%
Nov 6	Canaccord Genuity	Maintains	Buy → Buy	—	$11.48	$12.00	+4.5%	-1.7%	-2.1%	+3.0%	+8.4%	+3.1%
Sep 27	Craig-Hallum	Maintains	Buy → Buy	—	$11.05	$11.52	+4.3%	+5.3%	+8.1%	+6.7%	+6.6%	+5.6%
Aug 13	Canaccord Genuity	Maintains	Buy → Buy	—	$7.56	$7.57	+0.1%	+4.5%	+5.8%	+9.5%	+14.8%	+5.8%
Aug 7	Craig-Hallum	Maintains	Buy → Buy	—	$8.09	$8.36	+3.3%	-7.8%	-6.1%	-6.2%	-6.6%	-2.3%
May 8	Canaccord Genuity	Maintains	Buy → Buy	—	$5.12	$5.40	+5.5%	-1.6%	+6.6%	+5.5%	+11.7%	+17.0%
Mar 13	Craig-Hallum	Maintains	Buy → Buy	—	$5.60	$5.70	+1.8%	-5.5%	-7.3%	-2.7%	-2.0%	-3.6%
Dec 7	Canaccord Genuity	Upgrade	Hold → Buy	—	$4.52	$4.80	+6.2%	+13.1%	+11.5%	+9.5%	+7.3%	+6.2%
Apr 3	Craig-Hallum	Maintains	Hold → Hold	—	$1.07	$1.09	+1.9%	+5.6%	+2.8%	+15.9%	+22.4%	+8.4%
Nov 30	Goldman Sachs	Maintains	Neutral → Neutral	—	$1.88	$1.86	-1.1%	+3.7%	+15.4%	+13.3%	+19.7%	+17.0%
Nov 22	Craig-Hallum	Downgrade	Buy → Hold	—	$1.88	$1.82	-3.2%	-3.7%	+16.5%	+30.3%	+3.7%	+0.0%
Nov 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$2.58	$2.68	+3.9%	+25.6%	+28.7%	+22.1%	+27.1%	+15.1%
Nov 9	Canaccord Genuity	Downgrade	Buy → Hold	—	$3.00	$2.90	-3.3%	-14.0%	+8.0%	+10.7%	+5.0%	+9.3%
Nov 9	JP Morgan	Downgrade	Overweight → Underweight	—	$3.00	$2.90	-3.3%	-14.0%	+8.0%	+10.7%	+5.0%	+9.3%
Oct 11	Morgan Stanley	Maintains	Overweight → Overweight	—	$6.95	$6.83	-1.7%	-3.5%	-7.1%	-7.3%	-13.2%	-3.6%
Sep 7	Goldman Sachs	Maintains	Neutral → Neutral	—	$7.62	$7.53	-1.2%	-2.0%	+3.5%	+6.4%	+10.9%	+7.6%
Aug 12	Morgan Stanley	Maintains	Overweight → Overweight	—	$8.42	$8.45	+0.4%	+7.8%	+5.1%	+6.9%	+3.3%	+0.6%
May 12	Morgan Stanley	Maintains	Overweight → Overweight	—	$7.49	$7.47	-0.3%	+7.5%	+15.0%	+14.0%	+21.5%	+16.3%
Mar 21	Goldman Sachs	Maintains	Neutral → Neutral	—	$14.08	$13.96	-0.9%	-2.5%	-2.0%	-8.2%	-7.4%	-7.5%
Mar 15	Craig-Hallum	Maintains	Buy → Buy	—	$12.66	$13.68	+8.1%	+6.2%	+8.7%	+11.1%	+11.2%	+8.5%
Mar 11	Morgan Stanley	Maintains	Overweight → Overweight	—	$14.03	$14.18	+1.1%	-0.4%	-9.8%	-4.1%	-1.9%	+0.2%
Jul 1	Goldman Sachs	Downgrade	Buy → Neutral	—	$17.60	$16.75	-4.8%	-2.2%	-6.2%	-5.9%	-8.8%	-7.7%
Apr 19	Morgan Stanley	Maintains	Overweight → Overweight	—	$14.82	$14.99	+1.1%	-0.3%	+2.7%	-0.5%	-3.5%	-4.9%
Mar 8	Goldman Sachs	Maintains	Buy → Buy	—	$11.49	$12.01	+4.5%	+0.2%	+7.4%	+9.0%	+21.8%	+24.9%
Mar 8	Morgan Stanley	Maintains	Overweight → Overweight	—	$11.49	$12.01	+4.5%	+0.2%	+7.4%	+9.0%	+21.8%	+24.9%
Mar 8	JP Morgan	Maintains	Overweight → Overweight	—	$11.49	$12.01	+4.5%	+0.2%	+7.4%	+9.0%	+21.8%	+24.9%
Mar 8	Canaccord Genuity	Maintains	Buy → Buy	—	$11.49	$12.01	+4.5%	+0.2%	+7.4%	+9.0%	+21.8%	+24.9%

Recent Filings

8-K

Bioventus Inc. -- 8-K Filing

Bioventus reported strong Q4 2025 results with above-market growth and margin improvements, while providing 2026 guidance after strengthening its portfolio and balance sheet.

Mar 5

Data updated apr 24, 2026 11:17pm · Source: massive.com